| Tue 20 Nov 2007, 11:10 | | APN - Aspen Pharmacare Holding Limited - Press Rel |
|
APN
APN
APN - Aspen Pharmacare Holding Limited - Press Release
Aspen Pharmacare Holding Limited
(Incorporated in the Republic of South Africa)
Registration Number 1985/002935/06
Share code: APN
ISIN: ZAE000066692
Press Release
Aspen Strides One
ASPEN AND STRIDES ENTER INTO BROAD AND STRATEGIC PARTNERSHIP
Johannesburg South Africa, and Bangalore, India: Aspen Pharmacare (Aspen),
Africa`s largest pharmaceutical manufacturer and the largest generics
manufacturer in the southern hemisphere, has entered into a series of
transactions with Bangalore-based Strides Arcolab Limited (Strides), one of
India`s largest exporters of pharmaceutical products.
The transactions comprise:
* the acquisition by Aspen of 50% of Strides` Latin American operations
("Strides Latina"). Strides Latina is an operation owned by Strides Arcolab
Limited mainly operating in Brazil as Cellofarm and in Mexico as Solara,
with a marketing and trading operation in Venezuela as Sumifarma;
* the formation of a 50% joint venture with Strides to develop, manufacture
and commercialise a range of oncology products on a global basis through
Powercliff Limited ("Powercliff") and Onco Therapies Limited ("Onco");
* the acquisition by Strides of a 51% interest in Co-pharma Limited ("Co-
pharma"), Aspen`s 100% owned United Kingdom-based subsidiary; and
* the acquisition by Strides of 80% of the equity in Formula Naturelle (Pty)
Ltd which will, in turn, own a basket of nutraceutical products currently
marketed by Aspen Pharmacare in South Africa.
Arun Kumar, Strides` Vice Chairman and Group CEO said "we are delighted to
enhance the already rewarding partnership with Aspen and to broaden the
strategic relationship into a global partnership through the four transactions
being announced today.
Aspen has been Strides` first key partner and I am particularly delighted that
the partnership has grown, based on strong fundamentals of capability and trust.
\more
Aspen Strides Two
It has always been a delight working with Aspen and with this new alliance, and
I am extremely confident that we will create significant new value for both
companies. Having worked with Stephen Saard, Gus Attridge, Aspen`s Deputy Group
CEO and their management team this strategic conclusion will be ground breaking
in many respects and Strides looks forward to working closely with Aspen to
create a solid regional Pharma company in Latin America. The opportunity to
create a leading oncolytics operation in a niche and difficult domain, bodes
well for the Oncolytics JV."
Stephen Saad, Aspen Group Chief Executive said "we have worked closely with
Strides since 2003. The close collaboration of the past 4 years has resulted in
Strides becoming a significant manufacturing and development partner to Aspen in
both Africa and Australasia.
Today, I am happy to announce that we will forge an even closer partnership.
This partnership will be extended to Latin America, Global Oncolytics, Co-pharma
in the UK, and Nutraceuticals in South Africa.
It has always been a part of the Aspen strategy to enter the Latin American
pharmaceutical market. However, until now, we had been unable to find a
platform company through which to enter these markets. We were fortunate enough
that, through Strides, we have a partner who has had experience and success in
this market. Cellofarm is the number two player in the Brazilian hospital
market. Furthermore, it has sufficient presence to begin the process of
leveraging Aspen`s extensive product portfolio into these markets. The addition
of Aspen`s existing intellectual property (IP), Aspen`s front end marketing
capabilities, and the combined pipelines of Strides will give impetus to
Cellofarm in these branded generic markets. These markets are challenging and
have high barriers to entry and, given this launch pad, they should prove key
markets into the future for leveraging the significant IP that already vests
with Aspen, as well as roll-out of the local manufacturing facilities.
Strides and Aspen have a shared vision regarding sterile manufacture and the
extension to Oncolytics will complete the basket to the existing capabilities
that we are developing around hormonal and other sterile capabilities.
\more
Aspen Strides Three
We are excited by the opportunity these initiatives offer our organisations. I
would also like to thank Arun Kumar the Vice Chairman and Managing Director of
Strides and his team for their efforts in achieving the above. Aspen has been
privileged to have enjoyed this close partnership with Strides and from this we
have drawn much confidence as we take this partnership to the next level."
These investments in Latin America and Oncolytics are important strategic steps
in the internationalisation of Aspen which I expect to be value enhancing for
Aspen`s shareholders in the medium term.
Furthermore, we have sold a majority share in Co-pharma and our South African
Nutraceuticals business. We believe the Strides business model is better suited
to creating value in these businesses."
The completion of the transactions is subject to the signing of legal agreements
and is subject to the Exchange Control approval of the South African Reserve
Bank and the approval of the Reserve Bank of India and Strides` bankers and
other financial institutions, as appropriate.
\ends
Issued by: Shauneen Beukes, Shauneen Beukes Communications
Tel: +27 12 661 8467 : Cell: 082 389 8900
Fax: +27 088 12 661 8467
On Behalf Of: Stephen Saad, Aspen Group CE
Tel: +27 31 580-8602
Fax: +27 31 580 8640
Gus Attridge, Aspen Deputy Group CE
Tel: +27 31 5808604
Fax: +27 31 580 8640
www.aspenpharma.com
Arun Kumar, Strides Vice Chairman & MD or
Ravi Seth, Strides Group CFO
Tel: +91 80 6658 0110
Fax: +91 80 6658 0200
www.stridesarco.com
Harini Iyengar, Adafctors PR, Bangalore
Tel: +91 80 4113 32062/64
Fax: +91 80 4113 3059
\more
Aspen Strides Four
The Transactions
Details of each of the transactions outlined above are as follows:
(a) Aspen will acquire a 50% interest Strides Latina via the acquisition of
shares from Strides for US$ 58.5 million and the subscription for shares in
Strides-Aspen Latina (owned 100% by Strides) for US$94 million. This
consideration is subject to adjustment should the earnings for the year
following the effective date not reach certain levels. Following the first
year after the effective date, Aspen will have an option to buy, and
Strides to sell, Strides remaining 50% interest in Strides Latina.
(b) Aspen and Strides will enter into a 50% joint venture to develop,
manufacture and commercialise oncology products. Aspen will purchase 50%
of the issued share capital of Powercliff from Strides for US$25.75 million
and will subscribe for 49% of the share capital of Onco and issued debt
instruments for US$16.7 million. Aspen has the right to acquire a further
1% of the share capital of Onco for US$340,000..
(c) Strides will acquire a 51% interest in Co-pharma Limited ("Co-pharma"),
Aspen`s United Kingdom subsidiary, by means of the purchase of a portion of
Aspen`s shareholding in Co-pharma for GBP2.25 million and the subscription
for new shares for GBP375,000. At a later date Aspen has an option to
sell, and Strides to purchase, Aspen`s remaining interest in Co-pharma.
(d) Strides will subscribe for 80% of the equity of Formule Naturelle (Pty)
Limited, a 100% owned dormant subsidiary of Aspen. The subscription price
will be the R35 million. Formula Naturelle (Pty) Ltd will then acquire the
subject business from Aspen for the funds raised by way of the
subscription. Following the first year after the effective date, Aspen has
an option to sell, and Strides to purchase, Aspen`s remaining interest in
Formule Naturelle.
Background Information
Strides Latina
Strides Latina currently comprises two operations namely Cellofarm in Brazil,
and Solara in Mexico. In addition to these two companies, a further two trading
operations, Sumifarma and Mexicana, are in the process of being established in
Venezuela and Mexico respectively. Cellofarm and Solara were formed in the
early 2000`s and they both sell a range of generic products in a number of
therapeutic areas, with a particular focus on sterile products in the hospital
market. The products are either imported from Strides` manufacturing facilities
in India or are manufactured locally. Revenues for the year ended 31 December
2006 for Cellofarm and Solara were US$69 million and US$6 million respectively.
Both Cellofarm and Solara have solid dosage manufacturing facilities locally and
Cellofarm is in the process of completing the construction of a sterile
manufacturing facility in Brazil.
Powercliff and Onco
These two companies have been established by Strides to house a greenfield
generic oncology business, including the manufacturing and research and
development operations located at a production facility in India which is
nearing completion and which, prior to this transaction taking place, will be
owned by Onco. An intellectual property pipeline relating to this business has
already been identified by Strides and the rights to 32 oncology products in
development will be acquired by Powercliff prior to the completion of this
transaction. As such, the operations will focus on the manufacture and
commercialisation of these initial products and the development of further
products.
more
Aspen Strides Last
Co-pharma
Co-pharma Limited sells a range of commodity generic products in the United
Kingdom. Turnover for the year ended 30 June 2007 amounted to GBP10.4 million.
Formule Naturelle (Pty) Ltd - Nutraceutical Products
Aspen Pharmacare currently markets a range of nutraceutical and health products
in South Africa, under brands such as Formule Naturelle, with the majority of
sales being through pharmacies and major retail chains. Revenue generated by
these products in the year ended 30 June 2007 was R40 million.
Rationale For The Transactions
Aspen has had a development and manufacturing relationship with Strides for a
number of years and discussions revealed an opportunity for the two parties to
form an alliance that would benefit from Strides` strong development and
manufacturing capabilities and Aspen`s proven marketing track record. All of
the transactions will endeavour to realise the synergy provided by the relative
strengths of Aspen and Strides.
Two key areas that Aspen has identified for its future growth are:
* Latin America - a large developing market where it can leverage its
substantial intellectual property portfolio; and
* Oncology, a therapeutic area with high barriers to entry which offers the
potential of superior returns to companies with access to quality
development, manufacturing and marketing capabilities and which adds
critical mass to Aspen`s planned portfolio of sterile products.
Aspen believes that these strategic investments should become value enhancing to
shareholders in the medium term.
Aspen has been seeking a business partner able to extract the potential offered
by Co-pharma`s distribution capabilities in the United Kingdom. Strides`
strengths in development and low cost, flexible manufacture will provide Co-
pharma with an improved product offering.
Aspen has taken the strategic decision to reduce its personal care and natural
products range within its Consumer Division by way of selective disposals. The
hiving-off of the nutraceuticals products is consistent with this objective.
Strides has significant manufacturing capabilities for soft gel products which
comprise a material portion of the nutraceutical range.
Sponsor: Investec Bank
Date: 20/11/2007 11:10:01 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
